Fenofibrate was found to induce apoptosis in triple-negative breast cancer cell lines, which involved the activation of the nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cell (NF-κB) pathways, as the effect could be almost totally blocked by an NF-κB-specific inhibitor. The induction of apoptosis by fenofibrate was, however, independent of PPARα expression status, as the PPARα antagonist GW6471 did not change apoptosis induction by fenofibrate [43]. Here, NFKB1 is linked to triple-negative breast carcinoma.